About
The IKP working group on PharmacoOmics & Lymphoma aims at a refined molecular biological characterization and risk stratification of malignant lymphomas using next generation sequencing and gene expression techniques. In addition, we are working on deciphering the proteomic and metabolomic landscape of lymphomas in order to identify new therapeutic targets that can subsequently be tested in in vitro, in vivo and ex vivo experiments.